Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PEGylated G-CSF plus active bone marrow protection for prevention of chemoradiotherapy-induced neutropenia in locally advanced cervical cancer
ChiCTR2100046911Phase 2Recruiting
- Sponsor
- Yibin Second People's Hospital
- Start
- Jun 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pegfilgrastim in Cervical Cancer (CC), sponsored by Yibin Second People's Hospital. Primary endpoint: Neutropenia. Started Jun 2021; status: recruiting.
02
Drugs
pegfilgrastim
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on ChiCTR2100046911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046911.